Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omr-IgG-am for West Nile Virus Neuroinvasive Disease
NCT00069316Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Sep 2003
- Primary completion
- Jun 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Omr-IgG-am in West Nile virus infection (WNV) (3 arms), sponsored by National Institutes of Health. Primary endpoint: Safety and Tolerability. Started Sep 2003; status: completed.
02
Drugs
Omr-IgG-am
03
Conditions
West Nile virus infection (WNV)
Beyond the preview
Go deeper on NCT00069316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069316.